MedTrace Logo

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

NCT00580125 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2012-04-18

No results posted yet for this study

Summary

The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.

Conditions

Interventions

DRUG

PF-00217830

PF-00217830 5 mg, oral capsule, once daily for 21 days

OTHER

Placebo

Placebo, oral capsule, once daily for 21 days

DRUG

Aripiprazole

Aripiprazole 15 mg, oral capsule, once daily for 21 days

DRUG

PF-00217830

PF-00217830 15 mg, oral capsule, once daily for 21 days

DRUG

PF-00217830

PF-00217830 2 mg, oral capsule, once daily for 21 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States
  • India
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00580125 on ClinicalTrials.gov